General information
Immatics N.V.
Paul-Ehrlich-Straße 15
72076 Tübingen, Baden-Württemberg
Germany
Contact person: Harpreet Singh, Chief Executive Officer
Company main phone: +49 (7071) 53970
Company main fax: +49 (7071) 5397900
Website: https://www.immatics.com
Year founded: | 2000
|
Source of foundation: | Spin-off from university |
Name of foundation source: | H.G. Rammensee's laboratory at the University of Tübingen, Germany |
No. of employees: |
Worldwide: 210 |
Corporate description / mission:
Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting immunotherapies for the treatment of cancer. The company is developing targeted TCR-based immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) consisting of autologous (ACTengine®) or allogeneic (ACTallo®) product classes and antibody-like TCR Bispecifics, also called T cell Engaging Receptors (TCER®).
State of ownership: Publicly listed on stock exchange
Headquarters: Yes
IPO (year): 2020
Categorization
Sector: |
- Biotechnology - Therapeutics and Diagnostics
|
Subsector: |
- Cell therapy
- Immunotherapy
|
Primary therapeutic areas: |
- Neoplasms / cancer / oncology
|
Business model: |
- In-licensing
- Out-licensing
- R&D
|
Customer segments: |
- Large biotech & big pharma
- Small biotech
|
Summary Products / Services / Technologies
Number of Biotech Products
Pre-clinical: | 7 | |
Phase I: | 4 | |
Phase II: | 1 | |
Description of products:
ACTengine® IMA203 (PRAME),
ACTallo® IMA30x,
TCER® IMA401 (MAGEA4/8), ect.
Special IP situation:
The XPRESIDENT technology is protected by granted patents and patent applications.
Technology used:
XPRESIDENT™
XCEPTOR®
Financing details
Fiscal year (end of) 2022
Revenues: | USD 172.83M | |
R&D expenses: | USD 106.78M | |
Net earnings: | USD 37.51M | |
No. of shares: | 80'397'800 | |
Market cap. / valuation: | USD 984.07M | |
Collaborations & Clients
Partnering strategy / collaborations:
Amgen
MDACC
MorphoSys
Roche
Genmab